首页|重构本草——威灵仙

重构本草——威灵仙

扫码查看
通过古籍文献调研、中医药现代研究成果的梳理,结合中医临床及中药学等学科领域内知名专家学者的认识及应用经验,归纳出威灵仙:功效主要为祛风湿,通经络,止痛,消骨鲠.症靶为骨关节疼痛、咽喉异物感.标靶为高血尿酸、消化道息肉.现代药理研究发现威灵仙及其有效成分具有抗炎、保护软骨、解痉、降低尿酸等作用.大剂量使用威灵仙(>50g)可能导致变态反应、消化道刺激症状,使用时应从小剂量开始,密切观察患者反应以保证用药安全.临床使用剂量为10~45g,内服时当根据不同疾病,或同一疾病的不同阶段进行辨证使用,并积极探索威灵仙用量与症靶、标靶的量效关系.
Reconstruction of Chinese materia medica-Chinese clematis root
Through the investigation of ancient books and the sorting of the modem research achievements of traditional Chinese medicine,combined with the understanding and application experience of famous experts and scholars in the fields of traditional Chinese medicine clinical medicine and science of Chinese materia medica,it is concluded that Chinese clematis root mainly has the effects of dispelling wind and eliminating dampness,dredging meridians and collaterals,relieving pain,and eliminating bone sticking.The symptom targets are joint pain,and sensation of foreign body in the throat.The biochemical indicator targets are hyperuricemia and gastrointestinal polyps.Modern pharmacology studies have found that Chinese clematis root and its active ingredients have the effects of anti-inflammatory,protecting cartilage,spasmolysis,and reducing uric acid.The use of high-dose Chinese clematis root(over 50g)may lead to allergic reactions and digestive tract symptoms.Therefore,when using this drug in clinical practice,doctors should start with small doses,and closely observe patient reactions to ensure medication safety.The clinical dodage is 10-45g.When taken orally,it should be used dialectically according to different diseases or different stages of the same disease,and the dose-effect relationship between the dosage of Chinese clematis root and the symptom target and biochemical indicator target should be explored actively.

Chinese clematis rootsymptom targetbiochemical indicator targetreconstruction of Chinese materia medicaclinical verification

郝瑞、赵旌屹、鲍婷婷、沈梦菲、李敏

展开 >

中国中医科学院广安门医院,北京 100053

北京中医药大学,北京 100029

威灵仙 症靶 标靶 重构本草 临床回归

国家中医药局中医药创新团队及人才支持计划中央高水平中医医院临床科研业务费专项

ZYYCXTD-D-202001HLCMHPP2023006

2024

长春中医药大学学报
长春中医药大学

长春中医药大学学报

CSTPCD
影响因子:0.916
ISSN:1007-4813
年,卷(期):2024.40(3)
  • 1
  • 22